Subtopic Deep Dive

← Retinoids in leukemia and cellular processes

Retinoic Acid in Acute Promyelocytic Leukemia
Research Guide

What is Retinoic Acid in Acute Promyelocytic Leukemia?

Retinoic Acid in Acute Promyelocytic Leukemia (APL) refers to the use of all-trans retinoic acid (ATRA) to induce differentiation of promyelocytic blasts via PML-RARα degradation in t(15;17) leukemia.

ATRA therapy targets the PML-RARα fusion protein from t(15;17) translocation, restoring normal myeloid differentiation (Kakizuka et al., 1991; de Thé et al., 1991). Initial clinical trials showed complete remission in 24 APL patients, including chemotherapy-resistant cases (Meng‐Er Huang et al., 1988; 2401 citations). Over 10 key papers document ATRA's evolution with arsenic trioxide combinations achieving high cure rates (Lo‐Coco et al., 2013; Wang and Chen, 2008).

Curated Papers

Key Challenges

Why It Matters

ATRA transformed APL from highly fatal to highly curable, with cure rates exceeding 90% via differentiation therapy (Wang and Chen, 2008; 1261 citations). Combination with arsenic trioxide reduced chemotherapy needs in low-to-intermediate-risk patients, improving outcomes without inferiority to standard regimens (Lo‐Coco et al., 2013; 1561 citations). HL-60 cell studies established ATRA's mechanism for promyelocyte maturation (Breitman et al., 1980; 1985 citations), guiding precision treatments and inspiring therapies for other leukemias (Grimwade et al., 2010).

Key Research Challenges

ATRA Resistance Mechanisms

Relapsed APL patients develop resistance after initial ATRA response, linked to PML-RARα mutations or altered pharmacokinetics (Shen et al., 1997). Studies in relapsed cases show variable arsenic trioxide efficacy post-ATRA (Shen et al., 1997; 1425 citations). Identifying biomarkers remains critical for overcoming this hurdle.

Optimizing Combination Therapies

Balancing ATRA with arsenic trioxide versus chemotherapy requires risk-stratified protocols for low-to-intermediate cases (Lo‐Coco et al., 2013). Cytogenetic refinements highlight prognostic impacts of rare abnormalities in APL subsets (Grimwade et al., 2010; 1924 citations). Long-term toxicity profiles need further delineation.

PML-RARα Degradation Pathways

t(15;17) fusion disrupts RARα function, requiring precise ATRA-induced degradation (Kakizuka et al., 1991; de Thé et al., 1991). Variable cellular responses in HL-60 models underscore pathway complexities (Breitman et al., 1980). Targeted enhancements for incomplete responders pose ongoing challenges.

Essential Papers

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

Meng‐Er Huang, YC Ye, S R Chen et al. · 1988 · Blood · 2.4K citations

Abstract Twenty-four patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (45 to 100 mg/m2/day). Of these, eight cases had been either nonresponsive or resista...

Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.

T. R. Breitman, Stuart E. Selonick, SJ Collins · 1980 · Proceedings of the National Academy of Sciences · 2.0K citations

The HL-60 cell line, derived from a patient with acute promyelocytic leukemia, proliferates continuously in suspension culture and consists predominantly (greater than 90%) of promyelocytes. These ...

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman et al. · 2010 · Blood · 1.9K citations

Abstract Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnorma...

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

Brunangelo Falini, Cristina Mecucci, Enrico Tiacci et al. · 2005 · New England Journal of Medicine · 1.9K citations

Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al. · 2013 · New England Journal of Medicine · 1.6K citations

ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana co...

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

Akira Kakizuka, Wilson H. Miller, Kazuhiko Umesono et al. · 1991 · Cell · 1.4K citations

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Zhixiang Shen, Guoqiang Chen, Jian-Hua Ni et al. · 1997 · Blood · 1.4K citations

Abstract The therapeutic effect of arsenic trioxide (As2O3 ) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATR...

Reading Guide

Foundational Papers

Start with Huang et al. (1988; 2401 citations) for initial ATRA trials in 24 patients, then Breitman et al. (1980; 1985 citations) for HL-60 mechanisms, followed by Kakizuka et al. (1991) and de Thé et al. (1991) on PML-RARα fusion.

Recent Advances

Lo‐Coco et al. (2013; 1561 citations) on ATRA+arsenic superiority; Wang and Chen (2008; 1261 citations) reviewing APL curability; Grimwade et al. (2010; 1924 citations) on cytogenetic refinements.

Core Methods

ATRA dosing (45-100 mg/m²/day; Huang 1988), HL-60 differentiation induction (Breitman 1980), PML-RARα detection via cytogenetics (Kakizuka 1991), and arsenic combination trials (Lo‐Coco 2013).

How PapersFlow Helps You Research Retinoic Acid in Acute Promyelocytic Leukemia

Discover & Search

Research Agent uses searchPapers and citationGraph on 'ATRA APL PML-RARα' to map 2501-citation Huang et al. (1988) as central node, revealing clusters around Lo‐Coco et al. (2013) combinations. exaSearch uncovers related arsenic trials; findSimilarPapers extends to Grimwade et al. (2010) cytogenetics.

Analyze & Verify

Analysis Agent applies readPaperContent to extract remission rates from Huang et al. (1988), then verifyResponse with CoVe cross-checks against Breitman et al. (1980) HL-60 data for mechanism consistency. runPythonAnalysis plots citation trends and GRADE scores evidence as high for ATRA efficacy (A-level for clinical trials).

Synthesize & Write

Synthesis Agent detects gaps in resistance mechanisms post-Lo‐Coco et al. (2013), flagging contradictions in relapse pharmacokinetics. Writing Agent uses latexEditText for APL therapy reviews, latexSyncCitations for 10-paper bibliographies, and exportMermaid to diagram PML-RARα degradation cascades.

Use Cases

"Analyze survival curves from ATRA vs ATRA+arsenic APL trials"

Research Agent → searchPapers('ATRA arsenic APL survival') → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Lo‐Coco et al. 2013 data) → researcher gets overlaid Kaplan-Meier plots with p-values.

"Draft LaTeX review on PML-RARα fusion mechanisms"

Synthesis Agent → gap detection (Kakizuka 1991 + de Thé 1991) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → researcher gets compiled PDF with figures and 2401-citation Huang reference.

"Find code for HL-60 differentiation simulations"

Research Agent → paperExtractUrls (Breitman 1980) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets verified Python scripts modeling retinoic acid dose-responses.

Automated Workflows

Deep Research workflow scans 50+ APL papers via searchPapers → citationGraph on Huang (1988) → structured report with GRADEd evidence tables. DeepScan's 7-step chain verifies ATRA mechanisms: readPaperContent (Kakizuka 1991) → CoVe → runPythonAnalysis on remission stats. Theorizer generates hypotheses on resistance from Shen et al. (1997) + Lo‐Coco (2013) patterns.

Try Doxa for Retinoic Acid in Acute Promyelocytic Leukemia Research

Frequently Asked Questions

What defines Retinoic Acid therapy in APL?

ATRA induces differentiation of APL blasts expressing PML-RARα fusion via t(15;17), achieving remission in resistant cases (Huang et al., 1988).

What are key methods in ATRA-APL research?

HL-60 cell differentiation assays (Breitman et al., 1980) and clinical trials combine ATRA with arsenic trioxide (Lo‐Coco et al., 2013; Shen et al., 1997).

What are foundational papers?

Huang et al. (1988; 2401 citations) first treated 24 APL patients; Breitman et al. (1980; 1985 citations) showed HL-60 differentiation; Kakizuka et al. (1991) identified PML-RARα.

What open problems exist?

ATRA resistance in relapses (Shen et al., 1997), optimizing low-risk combinations (Lo‐Coco et al., 2013), and rare cytogenetic impacts (Grimwade et al., 2010).